Amidst the battle against a new infectious threat, the fight against tuberculosis, one of humankind’s oldest recorded infectious diseases, is also progressing. Pretomanid – only the second TB drug to hit the market in over two decades – received conditional marketing approval Monday from the European Commission as part of a new, three-drug treatment regimen […] Continue reading ->
COVID-19 is on it’s way to becoming the deadliest infectious disease in the world this year, and could cause more deaths worldwide than the current deadliest infectious disease killer tuberculosis. Currently tuberculosis, one of humankind’s oldest known infectious diseases, takes the lives of some 1.8 million people per year. Global Deaths Due to Various Causes […] Continue reading ->
Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading ->
San Diego, US (4 October 2019) – A trial involving a safe, novel ingestible sensor connected to a paired mobile device that lets medical staff remotely monitor patients’ intake of tuberculosis (TB) medicine, has shown better results than directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest […] Continue reading ->
[TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading ->